Chinthrajah RS, Purington N, Andorf S, et al. - Researchers assessed the sustained impacts of peanut allergy oral immunotherapy (OIT) in a randomized long-term study in adults and children by a randomized, double-blind, placebo-controlled, phase 2 study of 152 people at the Sean N Parker Center for Allergy and Asthma Research at Stanford University (Stanford, CA, USA) with peanut allergy aged 7–55 years. According to results, the most prevalent adverse events were mild gastrointestinal symptoms, which were observed in 90 of 120 patients and skin disorders, which were detected in 50/120 patients. Adverse events in all groups declined over time. During the 3-year study, two candidates in the peanut groups had serious adverse events. Findings suggested that peanut OIT may desensitize individuals with peanut allergy to 4,000 mg peanut protein, but discontinuation, or even reduction to 300 mg daily, may increase the likelihood of recovery of clinical peanut reactivity. Since baseline blood tests associated with week 117 outcomes of treatment, this research may help with optimal patient selection for this therapy. There were no deaths related to therapy.